Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Christel Larbouret"'
Autor:
Alexandra Fauvre, Margot Machu, Audrey Merienne, Nadia Vie, Thomas Bessede, Mathilde Robin, Veronique Garambois, Clara Taffoni, Nadine Laguette, Nadine Gervois‐Segain, Anne Jarry, Nathalie Labarriere, Yves Allory, Christel Larbouret, Laurent Gros, Diego Tosi, David B. Solit, Philippe Pourquier, Nadine Houédé, Celine Gongora
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 9, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/909d3363b27643e8a03718ec78c8c871
Autor:
Emilia Rabia, Véronique Garambois, Christine Dhommée, Christel Larbouret, Laurie Lajoie, Yoan Buscail, Gabriel Jimenez-Dominguez, Sylvie Choblet-Thery, Emmanuelle Liaudet-Coopman, Martine Cerutti, Marta Jarlier, Patrice Ravel, Laurent Gros, Nelly Pirot, Gilles Thibault, Eugene A. Zhukovsky, Pierre-Emmanuel Gérard, André Pèlegrin, Jacques Colinge, Thierry Chardès
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity.
Externí odkaz:
https://doaj.org/article/8a10b603d78a414f85898e71f788257b
Autor:
Christophe Le Clorennec, Yassamine Lazrek, Olivier Dubreuil, Carla Sampaio, Christel Larbouret, Romain Lanotte, Marie-Alix Poul, Jean-Marc Barret, Jean-François Prost, André Pèlegrin, Thierry Chardès
Publikováno v:
Cell Communication and Signaling, Vol 17, Iss 1, Pp 1-16 (2019)
Abstract Background HER3/ErbB3 receptor deletion or blockade leads to tumor cell apoptosis, whereas its overexpression confers anti-cancer drug resistance through upregulation of protective mechanisms against apoptosis. We produced the anti-HER3 anti
Externí odkaz:
https://doaj.org/article/4b70fcb461494809aa475152be331389
Autor:
Emilia Rabia, Véronique Garambois, Julie Hubert, Marine Bruciamacchie, Nelly Pirot, Hélène Delpech, Morgane Broyon, Charles Theillet, Pierre-Emmanuel Colombo, Nadia Vie, Diego Tosi, Celine Gongora, Lakhdar Khellaf, Marta Jarlier, Nina Radosevic-Robin, Thierry Chardès, André Pèlegrin, Christel Larbouret
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
Chemoresistance, particularly to gemcitabine, is a major challenge in pancreatic cancer. The epidermal growth factor receptor (EGFR) and human epidermal growth factor receptors 2 and 3 (HER2, HER3) are expressed in many tumors, and they are relevant
Externí odkaz:
https://doaj.org/article/321dae94e99e49a6a55ffcb4d608277f
Autor:
Diego Tosi, Esther Pérez-Gracia, Salima Atis, Nadia Vié, Eve Combès, Mélissa Gabanou, Christel Larbouret, Marta Jarlier, Caroline Mollevi, Adeline Torro, Maguy Del Rio, Pierre Martineau, Céline Gongora
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background The irinotecan-induced phosphokinome changes in colorectal cancer (CRC) cells were used to guide the selection of targeted agents to be tested in combination with irinotecan. Methods Phosphokinome profiling with peptide arrays of
Externí odkaz:
https://doaj.org/article/331b86359be842c48cdcab8ae7113b70
Autor:
Yassamine Lazrek, Olivier Dubreuil, Véronique Garambois, Nadège Gaborit, Christel Larbouret, Christophe Le Clorennec, Gaelle Thomas, Wilhem Leconet, Marta Jarlier, Martine Pugnière, Nadia Vié, Bruno Robert, Céline Monnet, Khalil Bouayadi, Hakim Kharrat, Philippe Mondon, André Pèlegrin, Thierry Chardès
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 15, Iss 3, Pp 335-347 (2013)
Blockade of the human epidermal growth factor receptor 3 (HER3) and of the downstream phosphatidylinositide 3-kinase (PI3K)/AKT pathway is a prerequisite for overcoming drug resistance and to develop novel treatments for cancers that are not eligible
Externí odkaz:
https://doaj.org/article/b4bb9ea6da264287898535708be0be8f
Autor:
Christel Larbouret, Nadège Gaborit, Thierry Chardès, Mickaël Coelho, Emmanuelle Campigna, Caroline Bascoul-Mollevi, Jean-Pierre Mach, David Azria, Bruno Robert, André Pèlegrin
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 14, Iss 2, Pp 121-130 (2012)
We previously demonstrated the synergistic therapeutic effect of the cetuximab (anti-epidermal growth factor receptor [EGFR] monoclonal antibody, mAb)-trastuzumab (anti-HER2 mAb) combination (2mAbs therapy) in HER2low human pancreatic carcinoma xenog
Externí odkaz:
https://doaj.org/article/df911cfa8d0242e398f9e0c7cae97c67
Autor:
Alexandre Ho-Pun-Cheung, Hervé Bazin, Nadège Gaborit, Christel Larbouret, Patrick Garnero, Eric Assenat, Florence Castan, Caroline Bascoul-Mollevi, Jeanne Ramos, Marc Ychou, André Pèlegrin, Gérard Mathis, Evelyne Lopez-Crapez
Publikováno v:
PLoS ONE, Vol 7, Iss 7, p e37065 (2012)
Following the development of targeted therapies against EGFR and HER2, two members of the human epidermal receptor (HER) family of receptor tyrosine kinases, much interest has been focused on their expression in tumors. However, knowing the expressio
Externí odkaz:
https://doaj.org/article/7086be063c3a46c981423774685c6f89
Autor:
Thierry Chardès, André Pèlegrin, Jean-François Prost, Gérard Mathis, Jean-Marc Barret, Philippe Mondon, Marie-Alix Poul, Véronique Garambois, Yassamine Lazrek, Charline Ogier, Christel Larbouret, Olivier Dubreuil, Hervé Bazin, Christophe Le Clorennec
Supplemental Fig.S3. In pancreatic cancer cells, ch9F7-F11-Emb is a negative allosteric modulator of NRG1-mediated signaling. The low-fucose non-NRG1 competing allosteric anti-HER3 antibody ch9F7-F11-Emb inhibits in a dose-dependent manner NRG1-media
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca6f44107aaead5130a42c31d8cfc79
https://doi.org/10.1158/1535-7163.22503252.v1
https://doi.org/10.1158/1535-7163.22503252.v1
Autor:
Bruno Robert, Christel Larbouret, André Pèlegrin, Jean-Max Pasquet, Dany Chalbos, Charles Theillet, Nina Radosevic-Robin, Marta Jarlier, Muriel Busson, Imade Aït-Arsa, Audrey Sirvent, Clément Chevalier, Stanislas du Manoir, Myriam Chentouf, Wilhem Leconet
Supplementary Figure 1. AXL, MER and TYRO-3 expression in Triple Negative Breast Cancer (TNBC) cell lines and PDXs by Western blot analysis. Supplementary Figure 2. AXL mRNA expression in a large dataset of breast cancer tumors. Supplementary Figure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::023a6dc180a6d199242c3f56b2350681
https://doi.org/10.1158/1078-0432.22461975
https://doi.org/10.1158/1078-0432.22461975